TY - JOUR
T1 - Breast cancer risk in relation to type of estrogen contained in oral contraceptives
AU - Schlesselman, James J.
AU - Stadel, Bruce V.
AU - Murray, Pamela
AU - Lai, Sheng han
N1 - Funding Information:
This study was supported by interagency agreement l-YOl-HD-61204 between the Uniformed Services University of the Health Sciences and the National Institute of Child Health and Human Development. Our analyses are based upon data from the Cancer and Steroid Hormone Study, conducted by the Division of Reproductive Health, Center for Health Promotion and Education, Centers for Disease Control, Atlanta, Georoia. USA - Dr Howard Orv (Frincipal Investigator), Dr George L. Fubin, MS Linda A: Webster; MS Phyllis F. Winqo, Mr Mark Scally, Dr Nancy Lee, MS Michelle Mandel, Dr Roger Rochat, Dr Richard Sattin. Data Collection Centers Principal Investigators - Dr Raymond Greenberg (Atlanta), Dr J. Wister Meigs and Dr W. Douglas Thompson (Connecticut), Dr G. Marie Swanson (Detroit), Dr Elaine Smith (Iowa), Dr Dorothy Pathak and Dr Charles Key (New Mexico), Dr Donald Austin (San Francisco), Dr David Thomas (Seattle), Dr Joseph Lyon and Dr Dee West (Utah). Pathology Review Principal Investigators - Dr Fred Gorstein, Dr Robert McDivitt, and Dr Stanley Robboy. Project Consultants - Dr Lonnie Burnett, Dr Robert Hoover, Dr Peter Layde, Dr Herbert Peterson, Dr James J. Schlesselman, Dr David Schottenfeld, Dr Bruce V. Stadel, and Dr Colin White. Pathology Consultants - Dr Walter Bauer, Dr William Christopherson, Dr Deborah Gersell, Dr Robert Kurman, Dr Allen Paris, and Dr Frank Vellios.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1987/12
Y1 - 1987/12
N2 - We report analyses designed to address the recent hypothesis that women who use combination-type OCs containing ethinylestradiol (EE) are at increased risk of breast cancer before age 45, if use of such OCs occurs prior to first term pregnancy (FTP). Our findings, based on data from 1679 cases and 1689 controls, 20-44 years of age, from the population-based Cancer and Steroid Hormone Study, are against the hypothesis. The relative risk of breast cancer by duration of exclusive use prior to FTP of OCs containing EE is estimated to be 1.0 (1-12 months EE use), 1.2 (13-48 months EE use), and 0.9 (49+ months EE use). There was no evidence of a latent effect. Among parous women with 49+ months exclusive use prior to FTP of EE-containing OCs, the relative risk of breast cancer was estimated as 0.9 (0-4 years after FTP) and 0.6 (5-9 years after FTP). Among nulliparous women with 49+ months exclusive use of EE-containing OCs, the relative risk of breast cancer was estimated as 1.0 (0-4 years since first use), 0.7 (5-9 years since first use), and 1.1 (10-14 years since first use). With regard to exclusive use of OCs containing mestranol, parous women who used such preparations long-term before their FTP showed no alteration of breast cancer risk, even 15 years or more after pregnancy. Nulliparous women with exclusive use of ME-containing OCs did show elevations in breast cancer risk, but the magnitude of risk in relation to duration of use and latent interval shows no pattern that suggests a cause-effect relationship.
AB - We report analyses designed to address the recent hypothesis that women who use combination-type OCs containing ethinylestradiol (EE) are at increased risk of breast cancer before age 45, if use of such OCs occurs prior to first term pregnancy (FTP). Our findings, based on data from 1679 cases and 1689 controls, 20-44 years of age, from the population-based Cancer and Steroid Hormone Study, are against the hypothesis. The relative risk of breast cancer by duration of exclusive use prior to FTP of OCs containing EE is estimated to be 1.0 (1-12 months EE use), 1.2 (13-48 months EE use), and 0.9 (49+ months EE use). There was no evidence of a latent effect. Among parous women with 49+ months exclusive use prior to FTP of EE-containing OCs, the relative risk of breast cancer was estimated as 0.9 (0-4 years after FTP) and 0.6 (5-9 years after FTP). Among nulliparous women with 49+ months exclusive use of EE-containing OCs, the relative risk of breast cancer was estimated as 1.0 (0-4 years since first use), 0.7 (5-9 years since first use), and 1.1 (10-14 years since first use). With regard to exclusive use of OCs containing mestranol, parous women who used such preparations long-term before their FTP showed no alteration of breast cancer risk, even 15 years or more after pregnancy. Nulliparous women with exclusive use of ME-containing OCs did show elevations in breast cancer risk, but the magnitude of risk in relation to duration of use and latent interval shows no pattern that suggests a cause-effect relationship.
UR - http://www.scopus.com/inward/record.url?scp=0023552608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023552608&partnerID=8YFLogxK
U2 - 10.1016/0010-7824(87)90033-3
DO - 10.1016/0010-7824(87)90033-3
M3 - Article
C2 - 3446437
AN - SCOPUS:0023552608
SN - 0010-7824
VL - 36
SP - 595
EP - 613
JO - Contraception
JF - Contraception
IS - 6
ER -